Q-omics provides the consensus-scored SPAG6 profile across patient tissues and cancer cell-line models. SPAG6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SPAG6 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, SPAG6 RNA expression shows 13,118 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, LUSC, and TGCT as cancer lineages where SPAG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPAG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPAG6 survival associations across molecular data types. SPAG6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPAG6 RNA expression–survival associations across cancer types. High SPAG6 expression shows unfavorable associations in DLBC, LIHC, UCEC and ACC, but favorable associations in BRCA and SKCM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for SPAG6 RNA expression.
This table summarizes SPAG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPAG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPAG6 shows lower tumor expression in LUSC, KIRC, KICH, LUAD and COAD and higher tumor expression in LIHC. The LUSC box plot shows higher SPAG6 RNA expression in normal versus tumor tissue (log2 FC = −2.905, t-test p < 0.001).
This table shows molecular features associated with SPAG6 in patient tissues and cancer cell lines. In patient samples, SPAG6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPAG6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
